Literature DB >> 32296145

Rivaroxaban reduces ischaemic events in patients with PAD.

Karina Huynh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32296145     DOI： 10.1038/s41569-020-0385-9

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  Rivaroxaban in Peripheral Artery Disease after Revascularization.

Authors:  Marc P Bonaca; Rupert M Bauersachs; Sonia S Anand; E Sebastian Debus; Mark R Nehler; Manesh R Patel; Fabrizio Fanelli; Warren H Capell; Lihong Diao; Nicole Jaeger; Connie N Hess; Akos F Pap; John M Kittelson; Ivan Gudz; Lajos Mátyás; Dainis K Krievins; Rafael Diaz; Marianne Brodmann; Eva Muehlhofer; Lloyd P Haskell; Scott D Berkowitz; William R Hiatt
Journal:  N Engl J Med       Date:  2020-03-28       Impact factor: 91.245
  1 in total
  1 in total

Review 1.  Therapeutic angiogenesis-based strategy for peripheral artery disease.

Authors:  Jingxuan Han; Lailiu Luo; Olivia Marcelina; Vivi Kasim; Shourong Wu
Journal:  Theranostics       Date:  2022-06-27       Impact factor: 11.600
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.